Background: Given the marked activity of THAL in end-stage MM, TT2 was designed (1) to determine THAL’s activity in the context of intensive induction, tandem autotransplants, consolidation and maintenance therapies; and (2) to determine the prognostic implications of serial MRI and gene expression profiling (GEP).

Adjusting for prognostic variables in multivariate and pair-mate analyses, TT2 was superior to TT1 in terms of CR duration, event-free and overall survival. These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design.

2012年6月18日 · In TT1 (n =231), a phase II trial, induction therapy included three cycles of VAD (vincristine, doxorubicine, dexamethasone), high-dose cyclophosphamide for collection of peripheral blood stem...

2012年8月23日 · In the present study, we analyzed data from the Total Therapy 2 (TT2) trial, along with the 2 Total Therapy 3 (TT3) trials. TT2 patients were assigned randomly to either a control group (no thalidomide) or to the experimental group (thalidomide during induction, between transplantations, and during consolidation and maintenance).

TT2's major advance vis-à-vis TT1 pertained to the subgroup without cytogenetic abnormalities (CA), supporting the role of post-transplant consolidation therapy, whereas the improved survival of the CA subgroup on the experimental versus control arm of …

2005年11月16日 · We now report on the outcome of patients treated on the “no thalidomide” arm of TT2 (TT2-) in comparison to TT1, in order to evaluate the effect of dose-intensification during induction and post-transplant therapy. Patients and Methods: 231 patients were enrolled in TT1 (median follow-up, 11yr) and 345 in TT2- (median follow-up, 3.5yr).

2005年11月16日 · Background: Autotransplants have become the standard of care for patients with MM. TT2, a prospective randomized phase III trial, evaluated whether adding T, effective in end-stage MM, could improve the outcome of patients receiving melphalan (MEL200)-based tandem autotransplants.

2006年4月1日 · To evaluate the benefit of TT2's posttandem autotransplant consolidation chemotherapy and dexamethasone maintenance, outcomes were compared on TT2 without thalidomide (n = 345; median follow-up, 3.5 years) and on predecessor trial TT1 (n = 231; median follow-up, 11.5 years).

2012年10月1日 · Results of our Total Therapy 2 trial, randomizing approximately half the patients to receive thalidomide, show that overall and progression-free survival are linked to expression levels of the nuclear glucocorticoid receptor, NR3C1, with low expression imparting poorer outcomes in the control (no thalidomide) arm, which was overcome by the ...

Total therapy 3 (TT3), incorporating bortezomib up-front into a tandem transplant regimen for newly diagnosed multiple myeloma (MM), effected 2-year complete response (CR) estimates >90%, which appeared superior to results reported for total therapy 2 (TT2). With median follow-up times of 2 years …